Welcome to our dedicated page for Vivani Medical SEC filings (Ticker: VANI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vivani Medical, Inc. (VANI) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including Current Reports on Form 8-K, Annual Reports on Form 10-K, and Quarterly Reports on Form 10-Q. Vivani is a Delaware-incorporated, Nasdaq-listed clinical-stage biopharmaceutical company developing NanoPortal™-based long-acting GLP-1 implants and, through its Cortigent subsidiary, neuromodulation devices for vision restoration and stroke recovery.
In its recent Form 8-K filings, Vivani has reported material events such as equity financings via private placements and a registered direct offering of common stock, including details on share purchase agreements, gross proceeds, and reliance on exemptions from registration under Regulation D. Other 8-Ks furnish press releases covering business updates, preliminary financial information, and clinical data from the LIBERATE-1 Phase 1 study of NPM-115 and preclinical results for NPM-139. The company also uses 8-Ks to describe its plans and key dates related to the proposed spin-off of Cortigent, Inc.
Vivani’s periodic reports, referenced in its news releases, include its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, which the company cites for more detailed risk factors and financial information. These filings discuss topics such as operating losses, research and development expenses, cash position, and the risks associated with developing and commercializing its product candidates.
On Stock Titan, users can review Vivani’s filings as they are made available from EDGAR and use AI-powered summaries to understand the significance of individual documents, from capital-raising agreements and clinical program updates to shareholder meeting results and Cortigent spin-off disclosures.
Vivani Medical director and 10% owner Gregg Williams reported buying 1,351,351 shares of Vivani common stock in a private sale on January 27, 2026. The purchase price was $1.48 per share, matching the last reported Nasdaq sale price on January 23, 2026, for gross proceeds of $1,999,999.48.
After this transaction, Williams beneficially owns 32,714,660 shares directly and through related entities. These include 4,799,200 shares in his own name, 25,789,708 shares held by the Gregg G. Williams 2006 Trust, and additional holdings through several Williams family investment entities over which he has voting and dispositive power.
Vivani Medical, Inc. entered into two equity transactions on January 25, 2026. The company agreed to sell 1,351,351 common shares in a private placement to an entity affiliated with its board chairman at $1.48 per share, generating gross proceeds of about $2.0 million with no warrants, discounts, or placement fees. At the same time, Vivani arranged a registered direct offering of 1,689,200 common shares expected to raise roughly $2.5 million in gross proceeds under its existing shelf registration, paying a 7% cash fee to the placement agent plus up to $125,000 of expenses. Directors and officers agreed to a 60-day lock-up after the registered offering closes, limiting insider share sales during that period.
Vivani Medical, Inc. is conducting a registered direct offering of 1,689,200 shares of common stock at $1.48 per share, raising approximately $2.0 million in net proceeds. At the same time, an entity affiliated with director Gregg Williams has agreed to buy 1,351,351 additional shares in a concurrent private placement, expected to add about $1.9 million, for combined net proceeds of roughly $3.9 million. Vivani plans to use these funds, together with existing cash, to support research and clinical development of its long-acting drug implant programs, as well as working capital and general corporate purposes, and currently expects its cash resources to fund operations into mid 2027. Following the offering and the concurrent private placement, Vivani expects to have 81,206,080 shares of common stock outstanding, and notes that new buyers will experience dilution compared with earlier shareholders.
Vivani Medical, Inc. director and 10% owner Gregg Williams reported additional insider purchases of the company’s common stock. On January 15, 2026, he reported the purchase of 1,473,214 shares at $1.12 per share under a private sale tied to a March 26, 2025 share purchase agreement, with gross proceeds of $1,649,999.68. He also reported purchasing 264,551 shares at $1.26 per share through a separate private sale under an August 11, 2025 share purchase agreement, with gross proceeds of $333,334.26.
After these transactions, Williams is reported as beneficially owning a total of 31,363,309 shares of Vivani Medical common stock. This includes 4,799,200 shares held directly and additional shares held through the Gregg G. Williams 2006 Trust, Williams International Co. LLC, Sam Williams Family Investments LLC, and the Sam B. Williams 1995 Generation-Skipping Trust, over which he has voting and dispositive power.
Vivani Medical, Inc. disclosed that a director and 10% owner purchased common stock in two private sale transactions. One transaction covered 1,473,214 shares at $1.12 per share under a Share Purchase Agreement dated as of March 26, 2025, with gross proceeds of $1,649,999.68. A second transaction covered 264,551 shares at $1.26 per share under a Share Purchase Agreement dated as of August 11, 2025, with gross proceeds of $333,334.26, in each case priced at the last reported Nasdaq sale price on the day before the agreement date.
Following these purchases, the reporting person beneficially owns 29,625,544 shares of Vivani common stock held directly and through several trusts and investment entities, and Gregg Williams has voting and dispositive power over all of these shares.
Vivani Medical, Inc. insider activity: A reporting person who is both a director and 10% owner of VANI disclosed two private purchases of Vivani Medical common stock dated 11/15/2025. One transaction involved buying 1,473,214 shares at $1.12 per share under a Share Purchase Agreement dated March 26, 2025, with gross proceeds of $1,649,999.68. A second transaction involved buying 264,550 shares at $1.26 per share under a Share Purchase Agreement dated August 11, 2025, with gross proceeds of $333,333.00. After these transactions, the reporting person is shown as beneficially owning 27,887,779 shares of Vivani common stock through a combination of direct holdings, family trusts, and related entities over which Gregg Williams has voting and dispositive power.
Vivani Medical (VANI) filed its Q3 2025 10-Q, reporting continued operating investment as it advances subdermal GLP-1 implant programs. Cash and cash equivalents were $2.6 million at September 30, 2025, down from $18.4 million at year-end, with total assets of $25.0 million and stockholders’ equity of $1.3 million. Net loss was $6.5 million for the quarter and $20.0 million year-to-date, driven by R&D and G&A expenses.
The company highlighted clinical and portfolio progress: LIBERATE-1, the first-in-human study of its NanoPortal technology, met primary objectives with a positive safety and tolerability profile, informing plans to prioritize NPM-139 (semaglutide implant). Vivani outlined plans to initiate a Phase 1 study for NPM-139 in the first half of 2026, pending regulatory clearance. To support operations, Vivani entered equity purchase agreements expected to bring $18.6 million between September 30, 2025 and July 15, 2026, and subsequently raised approximately $6.0 million in a private placement and $9.7 million gross in a registered direct offering in October. Shares outstanding were 72,952,235 as of November 12, 2025.
Vivani Medical, Inc. furnished an 8-K announcing a business update and third quarter 2025 financial results via a press release, and provided a corporate slide presentation. The materials were furnished under Items 2.02 and 7.01 on November 13, 2025 and are available as Exhibits 99.1 (press release) and 99.2 (slides).
The company noted these materials are not deemed “filed” under the Exchange Act. Vivani also posted the current slide deck to the Investors section of its website.
Vivani Medical (VANI) director and 10% owner Gregg G. Williams reported purchasing 3,703,703 shares of common stock on 10/27/2025 at $1.62 per share in a private sale transaction under a Share Purchase Agreement dated 10/26/2025. The transaction totaled $5,999,998.86.
Following the trade, Williams beneficially owned 26,150,015 shares, comprising 4,799,200 held directly and 21,350,815 held indirectly.
Vivani Medical (VANI) secured new capital through two equity transactions. The company completed a private placement of 3,703,703 common shares at $1.62 per share, generating approximately $6.0 million in gross proceeds. No warrants, discounts, or placement fees were involved.
Concurrently, Vivani entered a registered direct offering for 6,000,000 common shares, with gross proceeds of approximately $9.7 million, before a 7.0% placement fee and up to $125,000 of reimbursable expenses paid to ThinkEquity. Directors and officers agreed to 60-day lock-ups from the closing of the registered offering. The registered sale is being made under the company’s effective Form S-3 shelf via a prospectus and prospectus supplement.
FAQ
What is the current stock price of Vivani Medical (VANI)?
What is the market cap of Vivani Medical (VANI)?
